Company intelligence / Profile preview

Provectis

Basel, Basel-Stadt, Switzerlandprovectis.ch ↗

Ownership: Private
Development stage: Other

Overview

Provectis is a Swiss-based healthcare company specializing in the commercialization and launch of innovative biopharma products. It partners with emerging and established pharmaceutical companies to bring advanced therapies—especially for unmet medical needs—to Europe, Asia, and the Middle East. The company offers expertise in clinical development support (including bridging studies), regulatory affairs, market access/pricing strategy, product lifecycle management, and brand maximization. Its focus includes rare diseases and differentiated formulations that address unmet needs in both developed and emerging markets.

Therapeutic areas: Rare DiseasesNeurologyDermatologyOphthalmologyOncology
Modalities: Small moleculeBiologicMedical device
Industry: Consulting

Partnerships

Partners with innovative biopharma companies for asset commercialization; specific names not disclosed publicly

Beyond the preview

Go deeper on Provectis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Provectis.

Explore the full profile